LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.
Location: Switzerland, Zurich, Schlieren
Employees: 11-50
Total raised: $39.5M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | Tenmile | tenmile.co... |
| 08.11.2023 | Adjuvant C... | adjuvantca... |
| 29.02.2024 | CARB-X | carb-x.org |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.02.2024 | Series A | $3M | - |
| 08.10.2023 | Series A | $36.5M | - |
Mentions in press and media 19
| Date | Title | Description |
| 08.08.2024 | New Frontiers in Vaccine Development and Cancer Treatment: A Dual Breakthrough | In the realm of healthcare, two recent developments shine like beacons of hope. LimmaTech Biologics is making strides in vaccine development, while GSK is redefining cancer treatment. Both stories reveal the relentless pursuit of innovation... |
| 08.08.2024 | The Battle Against Dementia: A New Dawn in Prevention and Awareness | Dementia looms like a shadow over millions. It’s a thief, stealing memories and identities. But recent studies shine a light on prevention. Almost half of dementia cases could be avoided. This revelation is a beacon of hope for families and... |
| 02.08.2024 | Seasoned chairpersons and board members back life sciences startups | Anaveon, a clinical-stage company specializing in developing treatments for diseases with immune system dysfunction, focusing on biologics that modulate cytokine functions to provide therapeutic benefit has appointed former Chair and CEO o... |
| 02.08.2024 | LimmaTech to receive €10 million in exclusive licensing agreement | LimmaTech Biologics is a clinical-stage startup developing vaccines for the prevention of life-threatening diseases such as Shigellosis which is caused by Shigella bacteria. Shigellosis is the second leading cause of fatal diarrheal diseas... |
| 01.03.2024 | A wave of success for LimmaTech | LimmaTech is a clinical stage biotech company that has built a robust pipeline of innovative vaccines using their proprietary self-adjuvanting and multi-antigen vaccine technology platform. The startup was awarded $2.2 million from the Com... |
| 02.02.2024 | New investment brings LimmaTech’s series A to CHF 40 million | Emerging antimicrobial resistance worldwide presents a serious public health threat. Inappropriate or excessive use of antibiotics has resulted in a major increase in bacterial resistance against the formerly effective drugs. LimmaTech aim... |
| 01.02.2024 | LimmaTech Biologics Raises Additional $3M in Series A | LimmaTech Biologics, a Schlieren, Switzerland-based developer of a multi-antigen vaccine platform, raised additional $3M in Series A funding. The ruond, which brought the total amount to $40M, was led by Tenmile. The new funding followed th... |
| 03.01.2024 | LimmaTech Biologics expands pipeline with a vaccine against a widespread bacterial pathogen | |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 10.10.2023 | Swiss-based LimmaTech Biologics raises €35M to combat emerging antimicrobial resistance | Read this article in: Zurich-based LimmaTech Biologics AG, a clinical-stage biopharmaceutical company, announced on Monday, October 9, that it has secured $37M (approximately €35M) in a Series A round of funding. The investment was co-led b... |
Show more